There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aura Biosciences Inc (AURA – Research Report) and Stereotaxis (STXS – Research Report) with bullish sentiments.
Aura Biosciences Inc (AURA)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Aura Biosciences Inc yesterday. The company’s shares closed last Thursday at $7.02, close to its 52-week low of $5.99.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aura Biosciences Inc with a $26.33 average price target, implying a 260.2% upside from current levels. In a report issued on November 8, JMP Securities also reiterated a Buy rating on the stock with a $21.00 price target.
See the top stocks recommended by analysts >>
Stereotaxis (STXS)
In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Stereotaxis, with a price target of $5.00. The company’s shares closed last Thursday at $1.51, close to its 52-week low of $1.33.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of
Currently, the analyst consensus on Stereotaxis is a Strong Buy with an average price target of $4.33, representing a 165.6% upside. In a report released yesterday, B.Riley Financial also reiterated a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AURA:
- Aura Biosciences price target lowered to $20 from $23 at Scotiabank
- Aura Biosciences 11M share Spot Secondary priced at $9.00
- Aura Biosciences announces common stock offering, no amount given
- Aura Biosciences reports agreement from FDA under SPA for CoMpass trial
- Aura Biosciences names Jill Hopkins CMO, Mark Plavsic CTO
